4D Pharma Is Latest Biotech Casualty After Creditor Calls Time
Third NASDAQ-Listed Biotech To Cease Trading In 2022
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.

The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.